The CTLA-4 -1661G>A polymorphism can be used as a predictor of chronic hepatitis B treatment response so that appropriate management and ongoing monitoring can be done to achieve treatment targets and prevent the progression of chronic hepatitis B. Further research is needed to determine the role of anti-CTLA-4 in increasing the virological response to TDF. Here, CTLA4 is linked to chronic hepatitis B virus infection.